Clinical effects of adjuvant hyperbaric oxygen therapy on peritoneal metastasis of gastric cancer
10.3760/cma.j.issn.1009-6906.2019.03.009
- VernacularTitle:高压氧辅助治疗对胃癌腹膜转移患者临床疗效及生活质量的影响
- Author:
Yifen LIU
1
;
Suping HOU
;
Cong LI
;
Yang XIAO
;
Guosun DENG
Author Information
1. 衡水市人民医院胃肠外科, 河北省衡水,053000
- Publication Type:Journal Article
- Keywords:
Hyperbaric oxygen;
Peritoneal metastasis of gastric cancer;
Short-term efficacy;
Quality of life;
Long-term efficacy
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2019;26(3):202-205
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effects of adjuvant hyperbaric oxygen ( HBO) therapy on peritoneal metastasis of gastric cancer. Methods A retrospective analysis was made on the 88 patients with peritoneal metastasis of gastric cancer admitted to the hospital from August 2014 to August 2016. The patients were divided into the observation group ( n =39 ) and the control group ( n =49 ) by different treatment methods. The control group was treated with chemotherapy, while the observation group received adjuvant HBO therapy in addition to the treatment received by the control group. After 2 courses of treatment, the short-term efficacy and acute and sub-acute toxicity were compared between the patients of the 2 groups, and the life quality of the patients was evaluated by using QLQ-C30. One-year medical follow up was made, and disease progression and survival time were compared between the patients of the 2 groups. Results The objective response rate (ORR) of the observation group and the control group were 53. 85％ and 46. 94％, respectively. There was no statistical difference, when comparison was made between the 2 groups(χ2 =0. 414, P=0. 520). The digestive tract and blood toxicity scores of the observation group were (1. 08 ± 0. 26)and (1. 01 ± 0. 22) respectively, which were significantly lower than (3. 26 ± 0. 62) and (1. 67 ± 0. 41) of the control group (P<0. 05). The median disease progression time of the observation group and the control group was respectively 6 months and 3 months, and the median survival time was respectively 8. 9 months and 5. 1 months, with the observation group all being superior to those of the control group ( P < 0. 05 ). The comprehensive scores of the life quality and physical function in the observation group were higher than those in the control group (P<0. 05). Conclusion HBO adjuvant therapy for gastric cancer patients with peritoneal metastasis has good short-term efficacy, and could slow disease progress, improve their life quality, and more importantly showed less adverse reactions.
